Publications
157
Citations
7,576
Est. group size
~18
Recurring co-author estimate
Active years
51
Publishing since 1976
Typically publishes in teams of ~15 · 6% small-team papers (≤3 authors) · across 18 venues
- A phase 1/2 study of donor-derived anti-CD33 CAR T-cell therapy (VCAR33) for relapsed/refractory AML after allogeneic HCT
Blood · 2026
- Clinical Outcomes in Orca-T and Registry-Based Post-Transplant Cyclophosphamide Patients: An Observational Comparison
Transplantation and Cellular Therapy · 2026
- Clinical Outcomes in Myelodysplastic Syndrome Patients Treated with Orca-T or Post-Transplant Cyclophosphamide Patients: A Registry-Based Comparison
Transplantation and Cellular Therapy · 2026
- Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial
Blood · 2025
- Remission of <i>TP53</i> -Mutant AML After Transplantation With Trem-Cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Followed by a Donor-Derived Anti-CD33 Chimeric Antigen Receptor T (VCAR33)
JCO Precision Oncology · 2025
- CT-262: A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T® Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant
Clinical Lymphoma Myeloma & Leukemia · 2025
- Orca-T improves chronic graph-versus-host disease free in patients with a broad range of demographic and clinical variables: Results of randomized, Phase 3 trial
Blood · 2025
- POSTER: CT-262 A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T® Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant
Clinical Lymphoma Myeloma & Leukemia · 2025
- Trial in Progress: Phase 1/2 Study of Donor-Derived Anti-CD33 Chimeric Antigen Receptor Expressing T Cells (VCAR33) in Patients with Relapsed or Refractory Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Transplantation and Cellular Therapy · 2024
- Cardiovascular Events After Hematopoietic Stem Cell Transplant
JACC CardioOncology · 2023
- Cardiovascular Risk Stratification of Patients Undergoing Hematopoietic Stem Cell Transplantation: The CARE‐BMT Risk Score
Journal of the American Heart Association · 2023
- Eine einzigartige dreifache Philadelphia Chromosom-Variante t(4;9;22)(q21;q34;q11.2) bei einem neu diagnostizierten Patienten mit chronischer myeloischer Leukämie in chronischer Phase
Kompass Onkologie · 2023
- Pneumocystis jirovecii Infection in autologous hematopoietic stem cell transplant recipients
Bone Marrow Transplantation · 2022
- Pneumocystis Jirovecii Infection in Autologous Hematopoietic Stem Cell Transplant Recipients
Transplantation and Cellular Therapy · 2022
- Type 1 interferon to prevent leukemia relapse after allogeneic transplantation
Blood Advances · 2021
- Blood×21
- Biology of Blood and Marrow Transplantation×17
- Transplantation and Cellular Therapy×16
- Bone Marrow Transplantation×4
- Nature Medicine×3
- Hannah Choe
Medicine · The Ohio State University
- Marcos de Lima
Medicine · The Ohio State University
- John E. Levine
Medicine · University of Michigan
- Ayman Saad
Medicine · The Ohio State University
- Julianna Roddy
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile